2026-06-14T03:37:45Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/72172024-09-27T08:31:12Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Campo, Gianluca author Pavasini, Rita author Morciano, Giampaolo author Lincoff, Michael A author C Gibson, Michael author Kitakaze, Masafumi author Lonborg, Jacob author Ahluwalia, Amrita author Ishii, Hideki author Frenneaux, Michael author Ovize, Michel author Galvani, Marcello author Atar, Dan author Ibáñez, Borja author Cerisano, Giampaolo author Biscaglia, Simone author Neil, Brandon J author Asakura, Masanori author Engstrom, Thomas author Jones, Daniel A author Dawson, Dana author Ferrari, Roberto author Pinton, Paolo author Ottani, Filippo author 2017-10 Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high [1]. A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion [2]. Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome [17]. Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil [3], [4], [5], [9], [10], [11], excluding a trial on metoprolol [12] and comparing trial with follow-up length <12 months versus those with longer follow-up [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. This article describes data related article titled "Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials" [17]. Data Brief. 2017; 14:197-205 10.1016/j.dib.2017.07.033 2352-3409 Data in brief 28795098 http://hdl.handle.net/20.500.12105/7217 Cyclosporin Follow-up Myocardial infarction Nicorandil PCI Reperfusion injury Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention